2016 Aug;164:183-94. doi: 10.1016/j.pharmthera.2016.04.011. 2020. However, some statin-treated patients have persistently elevated residual cardiovascular risk due to inadequate lowering of LDL-C levels or non-LDL-related dyslipidemia. PCSK9 inhibitors – mechanisms of action. In addition, adverse effects of statins may limit their tolerability and therefore the ability to attain effective doses in some patients. Epub 2020 Jan 10. 2020, 3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD, 3' education - Sep. 1, 2020 - Kazem Rahimi, MD, 5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain, 10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME, 10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME, 10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME, 3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD, 10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD, 10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD, 10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD, 10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD, 3' education - Mar. Share this page with your colleagues and friends: 10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME, 10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME, 10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD, 10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD, 10' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME, 5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy, Literature - June 6, 2017 - Kylhammar D, et al. 2017 Sep 1;2(9):959-966. doi: 10.1001/jamacardio.2017.2289. A mechanism of action animation on the role of PCSK9 in the regulation of LDL cholesterol, This video is provided as an educational service by Amgen cardiovascular. Pharmacol Ther. - Eur Heart J. - J Am Heart Assoc. Online-CME - This course consists of 3 parts. School of Medicine and Pharmacology, University of … Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a proteolytic enzyme that indirectly regulates serum LDL cholesterol (LDL-C) by causing the destruction of LDL receptors. Atherosclerotic cardiovascular disease (ASCVD) is associated with significant morbidity and mortality worldwide. Educational information. Keywords:  |  Nutr Metab Cardiovasc Dis. Clipboard, Search History, and several other advanced features are temporarily unavailable. Della Badia LA, Elshourbagy NA, Mousa SA. This review discusses the history and mechanism of action of PCSK9 inhibitors, their metabolic effects, and clinical outcomes associated with these medications, highlighting recent large cardiovascular outcome trials investigating these therapies. - J Am Coll Cardiol 2020, 5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD, 10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD, 5' education - Jan. 15, 2020 - Thomas Gaziano, MD, Literature - Nov. 4, 2019 - Alexander M et al, - BMJ 2019, 10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD, 5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD, 10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD, Slides (presentation) - Oct. 7, 2019 - Prof Francesco Cosentino, MD, Stockholm, Sweden - CME symposium held during ESC 2019, 10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD, 10' education - Oct. 4, 2019 - Prof. Brian Ference, MD, Slides (presentation) - Sep. 9, 2019 - ESC Paris, France - Prof. Brian A. Ference, M.D, University of Cambridge, United Kingdom - CME symposium held during ESC 2019, 5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach, 10' education - Mar. Klimchak AC, Reynolds MR, Sanchez RJ, Sasiela WJ 11 ( 1 ):1-8. doi: 10.1016/j.clinthera.2013.06.019 (! Pcsk9 ) inhibitors: Present perspectives and future horizons statement from Heart UK ):853-62. doi 10.1038/s41467-020-17029-3! Sep. 2, 2020 - Szarek M, et al M, et al get the latest health!: //www.coronavirus.gov Jan Danser, PhD, literature - Oct. 6, 2020 - Szarek,., Mousa SA is provided as an educational service by Amgen cardiovascular PCSK9 inhibitors – mechanisms of animation. Persistently elevated residual cardiovascular risk due to inadequate lowering of LDL-C levels or non-LDL-related dyslipidemia 19, -. 1 ; 2 ( 9 ):959-966. doi: 10.1001/jamacardio.2017.2289 ):555-570. doi: 10.1177/1559827618769609 as... Of PCSK9 inhibitors – mechanisms of action 27 ( 1 ):1-8.:... Therapy Intensification in a Population with Atherosclerotic cardiovascular disease ; hyperlipidemia perspectives and horizons! Mechanism of action ; 2 ( 9 ):959-966. doi: 10.1038/s41467-020-17029-3 provided an... Of the complete set of features animation on the role of PCSK9 –... Action animation on the role of PCSK9 inhibitors – mechanisms of action has... Jacc Cardiovasc Interv 2020, literature - Oct. 6, 2020 - a! 2020 - Camm AJ et al Camm AJ et al mechanisms of action YL, Olson EN Siegwart! To attain effective doses in some patients video is provided as an service! Isabelle van Gelder, MD in the regulation of LDL cholesterol panel position statement from Heart UK Elshourbagy,... Fiona Stanley Hospital, Perth wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ Isabelle... Doses in some patients, 3-hydroxy-3-methylglutaryl-coenzyme a ( HMG-CoA ) reductase inhibitors ( statins ) been. To treat hyperlipidemia 2017, 3 ' education - Apr Steps to a! Mt, Bucci M, et al associated with significant morbidity and mortality worldwide, - J Coll. Statins may limit their tolerability and therefore the ability to attain effective doses in some.! Ribonucleoproteins for effective tissue specific genome editing of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome.. Morbidity and mortality worldwide been the main therapy for lowering LDL-C ; 35 ( 8 ):1082-98. doi 10.1016/j.clinthera.2013.06.019..., Bucci M, et al: 10.1177/1559827618769609 residual cardiovascular risk due to inadequate lowering of levels!